- Sales Intelligence: Healthcare
- Posts
- Weekly Newsletter - 1.29.2025
Weekly Newsletter - 1.29.2025
Plus: Trump's first week. Why the healthcare sector faces uncertainty 🌐
Welcome to Sales Intelligence: Healthcare, the weekly newsletter for healthcare sales professionals. Now is the time to fine-tune your strategies, leverage cutting-edge insights, and set the tone for a successful year ahead. Ensure your campaigns not only engage but convert, driving growth and impact in this dynamic industry.
To ensure you continue receiving our newsletters, please add [email protected] to your contact list!

EDITOR’S PICK🎯
Sales enablement is often seen as the silver bullet for boosting revenue, but here’s the harsh reality: without proper change management, even the best enablement strategies are doomed to fail.
Why? Because new tools and processes can’t succeed if your team isn’t ready to embrace them. Adoption fatigue, resistance to change, and misalignment between leaders and reps can sabotage even the most well-intentioned efforts.
At Hive Perform, we believe sales enablement and change management must work hand-in-hand to drive lasting impact. It’s not just about rolling out shiny new systems; it’s about aligning people, processes, and technology to create a foundation for sustainable growth.
Curious how to make it happen? Read more here🔗

INDUSTRY INSIGHTS 🌐
AI continues to revolutionize the medtech industry in 2025, driving innovation and reshaping healthcare delivery. Among the notable trends is the increasing adoption of AI-powered diagnostics, which enhance accuracy and efficiency in disease detection. Personalized healthcare is gaining momentum, with AI leveraging patient data to tailor treatments. The integration of AI in surgical robotics is also advancing, offering greater precision and reducing recovery times. Additionally, regulatory bodies are adapting to the AI-driven landscape, introducing frameworks to ensure safety and efficacy. As AI becomes more embedded in medtech, its transformative impact promises improved patient outcomes and a more efficient healthcare ecosystem.
Trump's first week in office triggered major disruptions in life sciences and a withdrawal from the WHO, impacting vaccine manufacturers. Biopharma leaders displayed mixed reactions. Communication freezes and diversity cutbacks raised concerns for ongoing projects, notably in research involving sexual and gender minorities, shaping an uncertain future for the sector. |
The J.P. Morgan Healthcare Conference indicates cautious optimism in the biopharma industry. The biotech and pharmaceutical industries are set for a transformative year in 2025, driven by significant trends reshaping the landscape. The rise of artificial intelligence and machine learning is optimizing drug discovery and development, enabling faster and more cost-effective innovation. Meanwhile, the push for personalized medicine continues to grow, with advances in genetic testing and biomarkers driving tailored treatment strategies. The sector also faces increasing scrutiny over drug pricing, prompting calls for greater transparency and equitable access. Furthermore, investments in cell and gene therapies remain a focal point, with numerous companies advancing groundbreaking treatments. As regulatory landscapes evolve, the industry is poised for both opportunities and challenges, making 2025 a pivotal year for biotech and pharma.
The global Open MRI Systems Market is projected to reach $2.64 billion by 2032, fueled by technological advancements and patient comfort. Open MRI systems, with their design benefits, cater to various body types, offering non-invasive imaging solutions. Key growth drivers include technological progress, patient-centered care, and rising healthcare demand.
Moderna secured $590 million from the U.S. government for developing mRNA vaccines targeting potential pandemic influenza strains like H5N1. Partnering with BARDA, Moderna advances candidate mRNA-1018 to Phase 3 trials. This funding supports late-stage development, aiming to swiftly address emerging pandemic threats and augment existing vaccine technology. |

YOUR FEEDBACK MATTERS🗳️
What Did You Think of Today’s Edition? |

Sales Intelligence is a Contentive publication in the Sales & Marketing division